Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3927954,duration of adequate analgesia,"Maximum pain relief developed within 10-15 min and the average duration of adequate analgesia was 78 min with the lower dose and 45 min with the higher dose, but this difference was not statistically significant.",Clinical assessment and plasma pharmacokinetics associated with intramuscular or extradural alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3927954/),min,78,5386,DB00802,Alfentanil
,3927954,duration of adequate analgesia,"Maximum pain relief developed within 10-15 min and the average duration of adequate analgesia was 78 min with the lower dose and 45 min with the higher dose, but this difference was not statistically significant.",Clinical assessment and plasma pharmacokinetics associated with intramuscular or extradural alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3927954/),min,45,5387,DB00802,Alfentanil
,15581380,half-time,"By virtue of these distinctive pharmacokinetic properties, the context-sensitive half-time (i.e. the time required for the drug's plasma concentration to decrease by 50% after cessation of an infusion) of remifentanil remains consistently short (3.2 minutes), even following an infusion of long duration (> or =8 hours).",Remifentanil update: clinical science and utility. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15581380/),min,3.2,6722,DB00802,Alfentanil
,1923912,total-body clearance,"Noncompartmental pharmacokinetic analysis of the data revealed the following estimates (mean +/- SD): total-body clearance 3.24 +/- 2.23 ml/kg/minute, volume of distribution 0.54 +/- 0.21 L/kg, and elimination half-life 4.14 +/- 2.58 hours.",The disposition of alfentanil in neonates with respiratory distress. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923912/),[ml] / [kg·min],3.24,8481,DB00802,Alfentanil
,1923912,volume of distribution,"Noncompartmental pharmacokinetic analysis of the data revealed the following estimates (mean +/- SD): total-body clearance 3.24 +/- 2.23 ml/kg/minute, volume of distribution 0.54 +/- 0.21 L/kg, and elimination half-life 4.14 +/- 2.58 hours.",The disposition of alfentanil in neonates with respiratory distress. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923912/),[l] / [kg],0.54,8482,DB00802,Alfentanil
,1923912,elimination half-life,"Noncompartmental pharmacokinetic analysis of the data revealed the following estimates (mean +/- SD): total-body clearance 3.24 +/- 2.23 ml/kg/minute, volume of distribution 0.54 +/- 0.21 L/kg, and elimination half-life 4.14 +/- 2.58 hours.",The disposition of alfentanil in neonates with respiratory distress. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923912/),h,4.14,8483,DB00802,Alfentanil
,18467078,k1e,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.038,14909,DB00802,Alfentanil
,18467078,keo,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.043,14910,DB00802,Alfentanil
,18467078,k1e,"Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1).",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.04 to 0.47,14911,DB00802,Alfentanil
,18467078,EC50,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),[ng] / [ml],1.2-451,14912,DB00802,Alfentanil
,18467078,alpha,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),μv,18-109,14913,DB00802,Alfentanil
,8061260,clearance,"The set of Scott et al with the lowest clearance (2.4 mL/kg/min) shows the best accuracy (MDAPE: 19.5%) and precision (P10: -40%, P90: 16%).",Predictive accuracy of alfentanil infusion in coronary artery surgery: a prebypass study in middle-aged and elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061260/),[ml] / [kg·min],2.4,24143,DB00802,Alfentanil
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],150,26130,DB00802,Alfentanil
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],300,26131,DB00802,Alfentanil
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],600,26132,DB00802,Alfentanil
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),,40,26133,DB00802,Alfentanil
,9009935,V1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,4.98,28910,DB00802,Alfentanil
,9009935,V2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,9.01,28911,DB00802,Alfentanil
,9009935,V3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,6.54,28912,DB00802,Alfentanil
,9009935,Cl1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],2.46,28913,DB00802,Alfentanil
,9009935,Cl2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],1.69,28914,DB00802,Alfentanil
,9009935,Cl3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],0.065,28915,DB00802,Alfentanil
,9009935,Ke0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),1/[min],0.516,28916,DB00802,Alfentanil
,9009935,E0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,20,28917,DB00802,Alfentanil
,9009935,Emax,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,5.62,28918,DB00802,Alfentanil
,9009935,EC50,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[ng] / [ml],11.2,28919,DB00802,Alfentanil
,9009935,gamma,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),,2.51,28920,DB00802,Alfentanil
,7486179,V1,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg],19.2,32722,DB00802,Alfentanil
,7486179,V2,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg],99,32723,DB00802,Alfentanil
,7486179,V3,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg],2344,32724,DB00802,Alfentanil
,7486179,Cl1,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg·min],2.5,32725,DB00802,Alfentanil
,7486179,Cl2,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg·min],38,32726,DB00802,Alfentanil
,7486179,Cl3,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg·min],15,32727,DB00802,Alfentanil
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,0.7-1.0,32863,DB00802,Alfentanil
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,2.8-4.0,32864,DB00802,Alfentanil
,31802534,infusion rate,The mean propofol infusion rate was significantly higher in patients not monitored by BIS scores than in those who were (5.44 ± 2.12 vs 4.76 ± 1.84 mg/kg/h; P = 0.016).,Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31802534/),[mg] / [h·kg],5.44,34296,DB00802,Alfentanil
,31802534,infusion rate,The mean propofol infusion rate was significantly higher in patients not monitored by BIS scores than in those who were (5.44 ± 2.12 vs 4.76 ± 1.84 mg/kg/h; P = 0.016).,Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31802534/),[mg] / [h·kg],4.76,34297,DB00802,Alfentanil
,9265933,half-life,The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min).,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),min,16.8,34917,DB00802,Alfentanil
,9265933,T1/2 (keo)),The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min).,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),min,16.8,34918,DB00802,Alfentanil
,9265933,steady-state plasma concentration,The steady-state plasma concentration required to produce 50% of maximum analgesia (EC50) was 12.1 ng/ml (range: 2.9-29.8 ng/ml) and correlated with initial pain intensity.,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),[ng] / [ml],12.1,34919,DB00802,Alfentanil
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35144,DB00802,Alfentanil
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35145,DB00802,Alfentanil
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],6.6,35146,DB00802,Alfentanil
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35147,DB00802,Alfentanil
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],4.2,35148,DB00802,Alfentanil
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],6.6,35149,DB00802,Alfentanil
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],7.9,35150,DB00802,Alfentanil
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],7.9,35151,DB00802,Alfentanil
,10201688,CO,The CO of individual pigs varied from 1.33 to 6.44 l/min.,Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201688/),[l] / [min],1.33 to 6.44,35223,DB00802,Alfentanil
,3081598,serum clearance,"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),[ml] / [kg·min],5.2,37375,DB00802,Alfentanil
,3081598,volume of distribution at steady state (Vss),"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),[l] / [kg],0.47,37376,DB00802,Alfentanil
,3081598,elimination half-life,"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),min,97,37377,DB00802,Alfentanil
,3081598,fraction of alfentanil unbound in serum (fu),The mean fraction of alfentanil unbound in serum (fu) was 0.18 +/- 0.08.,The pharmacokinetics of alfentanil in gynecologic surgical patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),,0.18,37378,DB00802,Alfentanil
,6131992,terminal elimination half-life,The terminal elimination half-life was 88 min for alfentanil and 140 min for sufentanil.,Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),min,88,39734,DB00802,Alfentanil
,6131992,terminal elimination half-life,The terminal elimination half-life was 88 min for alfentanil and 140 min for sufentanil.,Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),min,140,39735,DB00802,Alfentanil
,6131992,plasma,"Six hours after a therapeutic dose, plasma levels were in the order of 3 and 0.3 ng ml-1 for alfentanil and sufentanil respectively.",Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),ng,0.3,39736,DB00802,Alfentanil
,2503375,clearance,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[ml] / [kg·min],5.2,41034,DB00802,Alfentanil
,2503375,volume of distribution,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[1] / [kg],0.63,41035,DB00802,Alfentanil
,2503375,elimination half-life,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),min,96.9,41036,DB00802,Alfentanil
,7653804,elimination half-life of alfentanil (t1/2 beta),"However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups.",The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653804/),min,134,41869,DB00802,Alfentanil
,7653804,elimination half-life of alfentanil (t1/2 beta),"However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups.",The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653804/),min,143,41870,DB00802,Alfentanil
,7653804,elimination half-life of alfentanil (t1/2 beta),"However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups.",The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653804/),min,111,41871,DB00802,Alfentanil
,8750122,central compartment distribution volume (V1),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,31.2,43540,DB00802,Alfentanil
,8750122,steady-state distribution volume (Vdss),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,499,43541,DB00802,Alfentanil
,8750122,total clearance (Cltot),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),[ml] / [min],1001,43542,DB00802,Alfentanil
,8750122,redistribution half-life (t1/2 gamma),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,90,43543,DB00802,Alfentanil
,8750122,elimination half-life (t1/2 beta),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,558,43544,DB00802,Alfentanil
,8750122,V1,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,31.9,43545,DB00802,Alfentanil
,8750122,Vdss,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,124,43546,DB00802,Alfentanil
,8750122,Cltot,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),[ml] / [min],345,43547,DB00802,Alfentanil
,8750122,t1/2 gamma,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,36,43548,DB00802,Alfentanil
,8750122,t1/2 beta,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,275,43549,DB00802,Alfentanil
,3099599,volume of distribution at steady state,The volume of distribution at steady state was greater (P less than 0.02) in patients with renal failure (405 +/- 86 ml/kg) than in patients with normal renal function (281 +/- 97 ml/kg).,Pharmacokinetics of alfentanil in chronic renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),[ml] / [kg],405,47779,DB00802,Alfentanil
,3099599,volume of distribution at steady state,The volume of distribution at steady state was greater (P less than 0.02) in patients with renal failure (405 +/- 86 ml/kg) than in patients with normal renal function (281 +/- 97 ml/kg).,Pharmacokinetics of alfentanil in chronic renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),[ml] / [kg],281,47780,DB00802,Alfentanil
,3099599,plasma free fraction,Patients with renal failure had a higher (P less than 0.01) alfentanil plasma free fraction (0.19 +/- 0.06) than patients with normal renal function (0.11 +/- 0.03).,Pharmacokinetics of alfentanil in chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),,0.19,47781,DB00802,Alfentanil
,3099599,plasma free fraction,Patients with renal failure had a higher (P less than 0.01) alfentanil plasma free fraction (0.19 +/- 0.06) than patients with normal renal function (0.11 +/- 0.03).,Pharmacokinetics of alfentanil in chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),,0.11,47782,DB00802,Alfentanil
,1466226,concentration,The predicted median alfentanil concentration (289(256-363) ng ml-1) was significantly lower than the measured median plasma concentration of 368(168-666) ng ml-1).,Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466226/),[ng] / [ml],289,47783,DB00802,Alfentanil
,1466226,plasma concentration,The predicted median alfentanil concentration (289(256-363) ng ml-1) was significantly lower than the measured median plasma concentration of 368(168-666) ng ml-1).,Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466226/),[ng] / [ml],368,47784,DB00802,Alfentanil
,10631438,sedation score,The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period.,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,1,48719,DB00802,Alfentanil
,10631438,sedation score,The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period.,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,2 and 3,48720,DB00802,Alfentanil
,10631438,plasma concentrations,"At the same time, propofol plasma concentrations increased from 0.7 +/- 0.3 microgram/ml to 1.8 +/- 1.3 micrograms/ml.","[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),[μg] / [ml],0.,48721,DB00802,Alfentanil
,10631438,plasma concentrations,"At the same time, propofol plasma concentrations increased from 0.7 +/- 0.3 microgram/ml to 1.8 +/- 1.3 micrograms/ml.","[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,1,48722,DB00802,Alfentanil
,10631438,clearance,Alfentanil clearance was found to be reduced with four patients having extremely small clearance values (33 +/- 3 ml/min).,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),[ml] / [min],33,48723,DB00802,Alfentanil
,3919613,half-time,With fentanyl a significantly greater time lag was present (half-time = 6.4 +/- 1.3 min; mean +/- SD) than with alfentanil (half-time = 1.1 +/- 0.3 min).,EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),min,6.4,53033,DB00802,Alfentanil
,3919613,half-time,With fentanyl a significantly greater time lag was present (half-time = 6.4 +/- 1.3 min; mean +/- SD) than with alfentanil (half-time = 1.1 +/- 0.3 min).,EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),min,1.1,53034,DB00802,Alfentanil
,3919613,steady-state serum concentration,"The steady-state serum concentration that caused one-half of the maximal EEG slowing was 6.9 +/- 1.5 ng/ml for fentanyl, compared with 520 +/- 163 ng/ml for alfentanil.",EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),[ng] / [ml],6.9,53035,DB00802,Alfentanil
,3919613,steady-state serum concentration,"The steady-state serum concentration that caused one-half of the maximal EEG slowing was 6.9 +/- 1.5 ng/ml for fentanyl, compared with 520 +/- 163 ng/ml for alfentanil.",EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),[ng] / [ml],520,53036,DB00802,Alfentanil
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],2.8,53268,DB00802,Alfentanil
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],5.3,53269,DB00802,Alfentanil
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],0.42,53270,DB00802,Alfentanil
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,280,53271,DB00802,Alfentanil
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,120,53272,DB00802,Alfentanil
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,1030,53273,DB00802,Alfentanil
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],4.2,53274,DB00802,Alfentanil
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],8.8,53275,DB00802,Alfentanil
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],1.2,53276,DB00802,Alfentanil
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,62,53277,DB00802,Alfentanil
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,34,53278,DB00802,Alfentanil
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,211,53279,DB00802,Alfentanil
,2337359,serum concentration,Five minutes after a single dose of 20 micrograms/kg alfentanil median serum concentration was 66 ng/ml (range: 20-606).,Alfentanil pharmacokinetics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),[ng] / [ml],66,55357,DB00802,Alfentanil
,2337359,clearance,The median clearance was 0.87 ml/kg/min (range: 0.4-9.62) and median elimination half life 321 mins (64-1251).,Alfentanil pharmacokinetics in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),[ml] / [kg·min],0.87,55358,DB00802,Alfentanil
,2337359,elimination half life,The median clearance was 0.87 ml/kg/min (range: 0.4-9.62) and median elimination half life 321 mins (64-1251).,Alfentanil pharmacokinetics in preterm infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),min,321,55359,DB00802,Alfentanil
,2337359,steady state median,In four infants 20 micrograms/kg alfentanil given by infusion over 30 minutes followed by 5 micrograms/kg/hour produced steady state median alfentanil concentrations of 54.5 ng/ml (range: 7-73 ng/ml) with no evidence of drug accumulation.,Alfentanil pharmacokinetics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),[ng] / [ml],54.5,55360,DB00802,Alfentanil
,7999650,infusion rates,"Mean infusion rates were 9.3 +/- 2.1 mL/hour and 9.6 +/- 1.7 mL/hour for groups A and B, respectively.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),[ml] / [h],9.3,57278,DB00802,Alfentanil
,7999650,infusion rates,"Mean infusion rates were 9.3 +/- 2.1 mL/hour and 9.6 +/- 1.7 mL/hour for groups A and B, respectively.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),[ml] / [h],9.6,57279,DB00802,Alfentanil
,7999650,study duration,"Mean study duration was 3.7 hours in group A, and 3.0 hours in group B.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),h,3.7,57280,DB00802,Alfentanil
,7999650,study duration,"Mean study duration was 3.7 hours in group A, and 3.0 hours in group B.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),h,3.0,57281,DB00802,Alfentanil
,12621385,time to maximum concentration [T(max)],"Alfentanil was rapidly absorbed (time to maximum concentration [T(max)], 0.7 +/- 0.5 hour).",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,0.7,57943,DB00802,Alfentanil
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],27,57944,DB00802,Alfentanil
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],38,57945,DB00802,Alfentanil
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],57,57946,DB00802,Alfentanil
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],105,57947,DB00802,Alfentanil
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],16,57948,DB00802,Alfentanil
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],23,57949,DB00802,Alfentanil
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],31,57950,DB00802,Alfentanil
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],50,57951,DB00802,Alfentanil
,12621385,T,"T(max), elimination half-life (1.0 +/- 0.2 hours), total body clearance after oral administration (20 +/- 18 mL x kg(-1) x min(-1)), and dose-normalized AUC(infinity ) were independent of dose.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,1.0,57952,DB00802,Alfentanil
,12621385,elimination half-life,"T(max), elimination half-life (1.0 +/- 0.2 hours), total body clearance after oral administration (20 +/- 18 mL x kg(-1) x min(-1)), and dose-normalized AUC(infinity ) were independent of dose.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,1.0,57953,DB00802,Alfentanil
,12621385,total body clearance,"T(max), elimination half-life (1.0 +/- 0.2 hours), total body clearance after oral administration (20 +/- 18 mL x kg(-1) x min(-1)), and dose-normalized AUC(infinity ) were independent of dose.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ml] / [kg·min],20,57954,DB00802,Alfentanil
,12621385,Effect half-life,Effect half-life (1.3 +/- 0.9 hours) was similar to plasma half-life.,Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,1.3,57955,DB00802,Alfentanil
,8214905,PaCO2,"Positive pressure ventilation was begun, maintaining PaCO2 at 49.1 +/- 3.3 mm of Hg and airway pressure at 20 +/- 2 cm of H2O.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),h·mm,49.1,60921,DB00802,Alfentanil
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],94.8,60922,DB00802,Alfentanil
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],170.7,60923,DB00802,Alfentanil
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],390.9,60924,DB00802,Alfentanil
,2882701,elimination half-lives,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,3 to 4,62367,DB00802,Alfentanil
,2882701,steady-state volumes of distribution,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],2 to 4,62368,DB00802,Alfentanil
,2882701,hepatic clearances,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[ml] / [kg·min],10 to 20,62369,DB00802,Alfentanil
,2882701,terminal elimination half-life,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,1 1/2,62370,DB00802,Alfentanil
,2882701,steady-state volume of distribution,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],0.5 to 1,62371,DB00802,Alfentanil
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],5.3,65594,DB00802,Alfentanil
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],14.6,65595,DB00802,Alfentanil
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.1,65596,DB00802,Alfentanil
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,58,65597,DB00802,Alfentanil
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,35,65598,DB00802,Alfentanil
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,630,65599,DB00802,Alfentanil
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],4.9,65600,DB00802,Alfentanil
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],13.2,65601,DB00802,Alfentanil
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.5,65602,DB00802,Alfentanil
,18193918,clearance,The population distribution of propofol clearance was subsequently found to have a Gaussian distribution only in the log domain (mean value equivalent to 26.1 mL/kg/min).,Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],26.1,66480,DB00802,Alfentanil
,18193918,clearance,"The distribution in the normal domain was consequently asymmetric, with a slight predominance of patients with high values of clearance (5% and 95% confidence limits 17.7 and 42.1 mL/kg/min, respectively).",Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],5,66481,DB00802,Alfentanil
,18193918,clearance,"The distribution in the normal domain was consequently asymmetric, with a slight predominance of patients with high values of clearance (5% and 95% confidence limits 17.7 and 42.1 mL/kg/min, respectively).",Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],17.7,66482,DB00802,Alfentanil
,18193918,clearance,"The distribution in the normal domain was consequently asymmetric, with a slight predominance of patients with high values of clearance (5% and 95% confidence limits 17.7 and 42.1 mL/kg/min, respectively).",Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],42.1,66483,DB00802,Alfentanil
,12932070,elimination half-life,"The elimination half-life of alfentanil was similar in the control and atorvastatin groups (98.8 +/- 12.4 versus 98.3 +/- 11.3 min, respectively).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),min,98.8,69158,DB00802,Alfentanil
,12932070,elimination half-life,"The elimination half-life of alfentanil was similar in the control and atorvastatin groups (98.8 +/- 12.4 versus 98.3 +/- 11.3 min, respectively).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),min,98.3,69159,DB00802,Alfentanil
,12932070,Cl,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [min],0.20,69160,DB00802,Alfentanil
,12932070,Cl,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [min],0.22,69161,DB00802,Alfentanil
,12932070,Vdss,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [kg],0.38,69162,DB00802,Alfentanil
,12932070,Vdss,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [kg],0.39,69163,DB00802,Alfentanil
,12932070,AUC,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[mg·min] / [ml],0.05,69164,DB00802,Alfentanil
,12932070,AUC,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[mg·min] / [ml],0.04,69165,DB00802,Alfentanil
,2495860,Central-compartment volume of distribution,"Central-compartment volume of distribution was 0.131 +/- 0.087 L.kg-1 (mean +/- SD) in young healthy volunteers and decreased modestly with increasing age (r = -0.32, P less than 0.05).",Aging and alfentanil disposition in healthy volunteers and surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495860/),[l] / [kg],0.131,69526,DB00802,Alfentanil
,2495860,apparent volume of distribution at steady-state,"However, apparent volume of distribution at steady-state, 0.404 +/- 0.205 L.kg-1 for the whole study cohort, was not age-related.",Aging and alfentanil disposition in healthy volunteers and surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495860/),[l] / [kg],0.404,69527,DB00802,Alfentanil
,2495860,Plasma clearance,"Plasma clearance of alfentanil in young healthy subjects, 9.3 +/- 6.3 ml.kg-1.min-1, also showed an inverse relationship with age (r = -0.54, P less than 0.001), and was not affected by surgical stress in subjects older than 60 years.",Aging and alfentanil disposition in healthy volunteers and surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495860/),[ml] / [kg·min],9.3,69528,DB00802,Alfentanil
>,7952116,extraction efficiencies,"The extraction efficiencies for noralfentanil and alfentanil were > 99% and 70%, respectively.",Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952116/),%,99,70774,DB00802,Alfentanil
,7952116,extraction efficiencies,"The extraction efficiencies for noralfentanil and alfentanil were > 99% and 70%, respectively.",Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952116/),%,70,70775,DB00802,Alfentanil
,2878076,duration of action,"Alftentanil reaches its peak effect within 1 min after injection, and its duration of action is very short; at 2 times its MED50, 9r has a duration of action of 11 min.","Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878076/),min,11,70928,DB00802,Alfentanil
,28504483,absolute bioavailability,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%,55,78197,DB00802,Alfentanil
,28504483,absolute bioavailability,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%,41,78198,DB00802,Alfentanil
,28504483,mean absorption time,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),min,74,78199,DB00802,Alfentanil
,28504483,mean absorption time,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),min,6.7,78200,DB00802,Alfentanil
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,40,78201,DB00802,Alfentanil
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,41,78202,DB00802,Alfentanil
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,49,78203,DB00802,Alfentanil
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,50,78204,DB00802,Alfentanil
,8669668,central compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,6.0,79392,DB00802,Alfentanil
,8669668,second compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,49.5,79393,DB00802,Alfentanil
,8669668,third compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,429.3,79394,DB00802,Alfentanil
,8669668,Cl1 (elimination clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min],0.68,79395,DB00802,Alfentanil
,8669668,Cl2 (distribution clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min1],1.97,79396,DB00802,Alfentanil
,8669668,Cl3 (distribution clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min],0.70,79397,DB00802,Alfentanil
,8669668,V1,"The effects of CPB were optimally modeled by step changes in V1 and Cl1 to values of 15.9 and 1.95, respectively, with the institution of CPB.",Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),,15.9,79398,DB00802,Alfentanil
,8669668,Cl1,"The effects of CPB were optimally modeled by step changes in V1 and Cl1 to values of 15.9 and 1.95, respectively, with the institution of CPB.",Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),,1.95,79399,DB00802,Alfentanil
,8657433,duration,"Onset of pain relief was rapid, and duration was approximately 1.5 h with e.p. and 1 h with i.v. alfentanil.",A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8657433/),h,1.5,79795,DB00802,Alfentanil
,8657433,duration,"Onset of pain relief was rapid, and duration was approximately 1.5 h with e.p. and 1 h with i.v. alfentanil.",A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8657433/),h,1,79796,DB00802,Alfentanil
,10235658,distribution half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,37.24,80580,DB00802,Alfentanil
,10235658,elimination half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,482.69,80581,DB00802,Alfentanil
,10235658,clearance,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ml] / [min],1221.97,80582,DB00802,Alfentanil
,10235658,volume of distribution,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),l,736.46,80583,DB00802,Alfentanil
,10235658,plasma BN concentration,"The mean +/- SEM plasma BN concentration during CPB was 0.51+/-0.03 ng/ml which was adequate for the maintenance of analgesia and anaesthesia, as none of our patients expressed the signs and symptoms of awareness during surgery.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ng] / [ml],0.51,80584,DB00802,Alfentanil
,3094407,Cp50,"Plasma alfentanil concentrations required along with 66% N2O to obtain responses to single episodes of stimulation in 50% of the 37 patients (Cp50 +/- SE) were: 475 +/- 28 ng/ml for tracheal intubation, 279 +/- 20 ng/ml for skin incision, and 150 +/- 23 ng/ml for skin closure.",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],475,80857,DB00802,Alfentanil
,3094407,Cp50,"Plasma alfentanil concentrations required along with 66% N2O to obtain responses to single episodes of stimulation in 50% of the 37 patients (Cp50 +/- SE) were: 475 +/- 28 ng/ml for tracheal intubation, 279 +/- 20 ng/ml for skin incision, and 150 +/- 23 ng/ml for skin closure.",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],279,80858,DB00802,Alfentanil
,3094407,Cp50,"Plasma alfentanil concentrations required along with 66% N2O to obtain responses to single episodes of stimulation in 50% of the 37 patients (Cp50 +/- SE) were: 475 +/- 28 ng/ml for tracheal intubation, 279 +/- 20 ng/ml for skin incision, and 150 +/- 23 ng/ml for skin closure.",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],150,80859,DB00802,Alfentanil
,3094407,Cp50,"The Cp50 (mean +/- SD) for the three surgical procedures were: breast, 270 +/- 63 ng/ml (n = 12); lower abdominal, 309 +/- 44 ng/ml (n = 14); and upper abdominal, 412 +/- 135 ng/ml (n = 11).",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],270,80860,DB00802,Alfentanil
,3094407,Cp50,"The Cp50 (mean +/- SD) for the three surgical procedures were: breast, 270 +/- 63 ng/ml (n = 12); lower abdominal, 309 +/- 44 ng/ml (n = 14); and upper abdominal, 412 +/- 135 ng/ml (n = 11).",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],309,80861,DB00802,Alfentanil
,3094407,Cp50,"The Cp50 (mean +/- SD) for the three surgical procedures were: breast, 270 +/- 63 ng/ml (n = 12); lower abdominal, 309 +/- 44 ng/ml (n = 14); and upper abdominal, 412 +/- 135 ng/ml (n = 11).",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],412,80862,DB00802,Alfentanil
,3094407,Cp50,The Cp50 for satisfactory spontaneous ventilation after the discontinuation of N2O was 223 +/- 13 ng/ml.,Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],223,80863,DB00802,Alfentanil
,2876662,terminal half-life (t1/2 beta),"In the pregnant population terminal half-life (t1/2 beta), volume of distribution at steady state (Vdss), and total plasma clearance (Clp) amounted to 103 +/- 67 min, 541 +/- 155 ml/kg and 6.48 +/- 0.85 ml/kg-1/min-1, respectively (mean +/- SD), and did not differ significantly in nonpregnant patients.",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),min,103,81913,DB00802,Alfentanil
,2876662,volume of distribution at steady state (Vdss),"In the pregnant population terminal half-life (t1/2 beta), volume of distribution at steady state (Vdss), and total plasma clearance (Clp) amounted to 103 +/- 67 min, 541 +/- 155 ml/kg and 6.48 +/- 0.85 ml/kg-1/min-1, respectively (mean +/- SD), and did not differ significantly in nonpregnant patients.",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),[ml] / [kg],541,81914,DB00802,Alfentanil
,2876662,total plasma clearance (Clp),"In the pregnant population terminal half-life (t1/2 beta), volume of distribution at steady state (Vdss), and total plasma clearance (Clp) amounted to 103 +/- 67 min, 541 +/- 155 ml/kg and 6.48 +/- 0.85 ml/kg-1/min-1, respectively (mean +/- SD), and did not differ significantly in nonpregnant patients.",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),[ml] / [kg],6.48,81915,DB00802,Alfentanil
,2876662,protein,"In groups A and B the fetal-maternal ratios indicated a concentration gradient for the total plasma alfentanil content (ratio of total alfentanil concentrations in umbilical venous and maternal blood (Uv/M), 0.31 +/- 0.08 and 0.28 +/- 0.06 (mean +/- SD) in groups A and B respectively) with a larger protein binding capacity in maternal plasma (group A, 85 +/- 3%; group B, 90 +/- 1%) (mean +/- SD).",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),%,85,81916,DB00802,Alfentanil
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],876,83299,DB00802,Alfentanil
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],420,83300,DB00802,Alfentanil
,2885190,systemic clearance,"However, there was a greater systemic clearance (P = 0.02) when determined using the post-infusion decay data compared with that calculated during anaesthesia (527 ml min-1 compared with 434 ml min-1).",Alfentanil infusions: relationship between pharmacokinetics and pharmacodynamics in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885190/),[ml] / [min],527,83692,DB00802,Alfentanil
,2885190,systemic clearance,"However, there was a greater systemic clearance (P = 0.02) when determined using the post-infusion decay data compared with that calculated during anaesthesia (527 ml min-1 compared with 434 ml min-1).",Alfentanil infusions: relationship between pharmacokinetics and pharmacodynamics in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885190/),[ml] / [min],434,83693,DB00802,Alfentanil
,2501060,Elimination half-life,Elimination half-life increased significantly (p less than 0.01) after 7 days from the control value of 84.0 +/- 8.2 minutes to 131.4 +/- 43.5 minutes.,Inhibition of alfentanil metabolism by erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),min,84.0,84269,DB00802,Alfentanil
,2501060,Elimination half-life,Elimination half-life increased significantly (p less than 0.01) after 7 days from the control value of 84.0 +/- 8.2 minutes to 131.4 +/- 43.5 minutes.,Inhibition of alfentanil metabolism by erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),min,131.4,84270,DB00802,Alfentanil
,2501060,Clearance,Clearance was decreased significantly (p less than 0.05) from 3.9 +/- 0.8 ml/kg/min to 2.9 +/- 1.2 ml/kg/min after 7 days.,Inhibition of alfentanil metabolism by erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),[ml] / [kg·min],3.9,84271,DB00802,Alfentanil
,2501060,Clearance,Clearance was decreased significantly (p less than 0.05) from 3.9 +/- 0.8 ml/kg/min to 2.9 +/- 1.2 ml/kg/min after 7 days.,Inhibition of alfentanil metabolism by erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),[ml] / [kg·min],2.9,84272,DB00802,Alfentanil
,10589629,plasma concentrations,"Unbound ropivacaine plasma concentrations peaked after 15 min at 0.08+/-0.09 microg/mL; the maximum was 0.30 microg/mL, compared with a toxic threshold of 0.6 microg/mL.",Wound infiltration and drain lavage with ropivacaine after major shoulder surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589629/),[μg] / [ml],0.08,85621,DB00802,Alfentanil
,10589629,maximum,"Unbound ropivacaine plasma concentrations peaked after 15 min at 0.08+/-0.09 microg/mL; the maximum was 0.30 microg/mL, compared with a toxic threshold of 0.6 microg/mL.",Wound infiltration and drain lavage with ropivacaine after major shoulder surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589629/),[μg] / [ml],0.30,85622,DB00802,Alfentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00802,Alfentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00802,Alfentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00802,Alfentanil
,3921471,elimination half-life,The kinetics of the analgesic can be described by a two-compartment model; the elimination half-life has a mean value of 64.8 +/- 38.5 min.,Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921471/),min,64.8,86281,DB00802,Alfentanil
,3921471,elimination half-life,The mean elimination half-life is 29.4 +/- 6.2 min.,Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921471/),min,29.4,86282,DB00802,Alfentanil
,29803320,duration of examination,The average duration of examination were 2.9 ± 1.4 min for EGD and 6.6 ± 2.7 min for colonoscopy.,Plasma concentration based response surface model predict better than effect-site concentration based model for wake-up time during gastrointestinal endoscopy sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803320/),min,2.9,86879,DB00802,Alfentanil
,29803320,duration of examination,The average duration of examination were 2.9 ± 1.4 min for EGD and 6.6 ± 2.7 min for colonoscopy.,Plasma concentration based response surface model predict better than effect-site concentration based model for wake-up time during gastrointestinal endoscopy sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803320/),min,6.6,86880,DB00802,Alfentanil
,8489055,Cp50,"The Cp50 for fentanyl was 3.26 ng/ml, and the Cp50-BAR was 4.17 ng/ml.","Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489055/),[ng] / [ml],3.26,89419,DB00802,Alfentanil
,8489055,Cp50-BAR,"The Cp50 for fentanyl was 3.26 ng/ml, and the Cp50-BAR was 4.17 ng/ml.","Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489055/),[ng] / [ml],4.17,89420,DB00802,Alfentanil
,8638836,CLc,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[l] / [min],2.9,90497,DB00802,Alfentanil
,8638836,VDss,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),,21.81,90498,DB00802,Alfentanil
,8638836,terminal half-life,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,35.1,90499,DB00802,Alfentanil
,8638836,T(12)k(e0),"Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,0.75,90500,DB00802,Alfentanil
,8638836,T(12)k(e0),"Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,0.96,90501,DB00802,Alfentanil
,8638836,effective concentration for 50% maximal effect,"However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[ng] / [ml],19.9,90502,DB00802,Alfentanil
,8638836,effective concentration for 50% maximal effect,"However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[ng] / [ml],375.9,90503,DB00802,Alfentanil
,3118743,Vdss,"The mean value of Vdss was 0.419 (SE .028) l.kg-1) for the whole group, and elimination t1/2 was 76.3 (SE 6.5) min.",The pharmacokinetics of alfentanil in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118743/),[l] / [kg],0.419,92347,DB00802,Alfentanil
,3118743,elimination t1/2,"The mean value of Vdss was 0.419 (SE .028) l.kg-1) for the whole group, and elimination t1/2 was 76.3 (SE 6.5) min.",The pharmacokinetics of alfentanil in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118743/),min,76.3,92348,DB00802,Alfentanil
,3118743,clearance rate [TBC,The clearance rate [TBC = 7.9 (SE 0.41) ml.kg-1.min-1] was within the range of values previously determined in adult studies.,The pharmacokinetics of alfentanil in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118743/),[ml] / [kg·min],7.9,92349,DB00802,Alfentanil
,3099603,Total apparent volume of distribution (Vdss),Total apparent volume of distribution (Vdss) was 457 +/- 160 ml/kg in adults and 163 +/- 110 ml/kg in children (P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),[ml] / [kg],457,94559,DB00802,Alfentanil
,3099603,Total apparent volume of distribution (Vdss),Total apparent volume of distribution (Vdss) was 457 +/- 160 ml/kg in adults and 163 +/- 110 ml/kg in children (P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),[ml] / [kg],163,94560,DB00802,Alfentanil
,3099603,Terminal elimination half-life,Terminal elimination half-life was significantly shorter in children (40 +/- 9 min) than in adults (97 +/- 22 min; P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),min,40,94561,DB00802,Alfentanil
,3099603,Terminal elimination half-life,Terminal elimination half-life was significantly shorter in children (40 +/- 9 min) than in adults (97 +/- 22 min; P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),min,97,94562,DB00802,Alfentanil
,23895731,volume of distribution at steady-state,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95847,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.25,95848,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,2.18,95849,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,18.6,95850,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95851,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95852,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95853,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95854,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95855,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95856,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95857,DB00802,Alfentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95858,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95859,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95860,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95861,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95862,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95863,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95864,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95865,DB00802,Alfentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95866,DB00802,Alfentanil
,8818989,total volume of distribution,"In addition, endotoxin raised the total volume of distribution of alfentanil from 0.70 to 1.4 L/kg.",Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818989/),[l] / [kg],0.70,98093,DB00802,Alfentanil
,8818989,total volume of distribution,"In addition, endotoxin raised the total volume of distribution of alfentanil from 0.70 to 1.4 L/kg.",Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818989/),[l] / [kg],1.4,98094,DB00802,Alfentanil
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],876,99082,DB00802,Alfentanil
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],420,99083,DB00802,Alfentanil
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,6,101227,DB00802,Alfentanil
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,19,101228,DB00802,Alfentanil
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101229,DB00802,Alfentanil
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101230,DB00802,Alfentanil
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101231,DB00802,Alfentanil
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101232,DB00802,Alfentanil
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101233,DB00802,Alfentanil
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101234,DB00802,Alfentanil
,8439023,minimum effective CSF clonidine concentration,Extrapolation of CSF clonidine pharmacokinetics suggests the minimum effective CSF clonidine concentration for postoperative pain relief is 76 +/- 15 ng/ml.,Hemodynamic and analgesic actions of epidurally administered clonidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439023/),[ng] / [ml],76,101547,DB00802,Alfentanil
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],4.62,103388,DB00802,Alfentanil
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.69,103389,DB00802,Alfentanil
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.29,103390,DB00802,Alfentanil
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,47.4,103391,DB00802,Alfentanil
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,8.6,103392,DB00802,Alfentanil
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,2.8,103393,DB00802,Alfentanil
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,111,103394,DB00802,Alfentanil
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,89,103395,DB00802,Alfentanil
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,104,103396,DB00802,Alfentanil
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,2.8,103397,DB00802,Alfentanil
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,19.1,103398,DB00802,Alfentanil
,8466018,maximal serum concentrations,"The pharmacokinetics of alfentanil from the cerebrospinal fluid to the systemic circulation were linear, i.e., dose-independent with maximal serum concentrations of 0.6, 1.4, and 3.5 ng/mL 10 min after the three respective IT doses.",Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466018/),[ng] / [ml],0.6,103901,DB00802,Alfentanil
,8466018,maximal serum concentrations,"The pharmacokinetics of alfentanil from the cerebrospinal fluid to the systemic circulation were linear, i.e., dose-independent with maximal serum concentrations of 0.6, 1.4, and 3.5 ng/mL 10 min after the three respective IT doses.",Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466018/),[ng] / [ml],1.4,103902,DB00802,Alfentanil
,8466018,maximal serum concentrations,"The pharmacokinetics of alfentanil from the cerebrospinal fluid to the systemic circulation were linear, i.e., dose-independent with maximal serum concentrations of 0.6, 1.4, and 3.5 ng/mL 10 min after the three respective IT doses.",Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466018/),[ng] / [ml],3.5,103903,DB00802,Alfentanil
,2078976,volume of distribution,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[l] / [kg],0.84,107691,DB00802,Alfentanil
,2078976,volume of distribution,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[l] / [kg],0.82,107692,DB00802,Alfentanil
,2078976,clearance,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[ml] / [kg·min],1.35,107693,DB00802,Alfentanil
,2078976,clearance,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[ml] / [kg·min],1.7,107694,DB00802,Alfentanil
,2078976,effective half-life,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),min,455,107695,DB00802,Alfentanil
,2078976,effective half-life,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),min,328,107696,DB00802,Alfentanil
,1744940,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,21.65,110196,DB00802,Alfentanil
,1744940,clearance (Cl),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14.1,110197,DB00802,Alfentanil
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,55.95,110198,DB00802,Alfentanil
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,68.03,110199,DB00802,Alfentanil
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14,110200,DB00802,Alfentanil
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],13.6,110201,DB00802,Alfentanil
,8053579,steady-state volume of distribution,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),1,43.2,112419,DB00802,Alfentanil
,8053579,total plasma clearance,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),[ml] / [min],418,112420,DB00802,Alfentanil
,8053579,total plasma clearance,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),min,119,112421,DB00802,Alfentanil
,8053579,elimination half-life,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),[ml] / [min],418,112422,DB00802,Alfentanil
,8053579,mean residence time,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),min,103,112423,DB00802,Alfentanil
,8053579,systemic availability,The mean systemic availability and mean absorption time derived from the deconvolution data were 100 +/- 17% and 114 +/- 24 min.,Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),%,100,112424,DB00802,Alfentanil
,8053579,mean absorption time,The mean systemic availability and mean absorption time derived from the deconvolution data were 100 +/- 17% and 114 +/- 24 min.,Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),min,114,112425,DB00802,Alfentanil
,8280548,requirement,Mean intraoperative alfentanil requirement was greater in patients with Crohn's disease (2.48 micrograms kg-1 min-1) than in control patients (1.35 micrograms kg-1 min-1) (P < 0.01).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[μg] / [kg·min],2.48,112887,DB00802,Alfentanil
,8280548,requirement,Mean intraoperative alfentanil requirement was greater in patients with Crohn's disease (2.48 micrograms kg-1 min-1) than in control patients (1.35 micrograms kg-1 min-1) (P < 0.01).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[μg] / [kg·min],1.35,112888,DB00802,Alfentanil
,8280548,elimination half-life,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),min,80,112889,DB00802,Alfentanil
,8280548,total plasma clearance,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],5.7,112890,DB00802,Alfentanil
,8280548,total plasma clearance,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],6.4,112891,DB00802,Alfentanil
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],6.4,112892,DB00802,Alfentanil
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[l] / [kg],0.70,112893,DB00802,Alfentanil
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[l] / [kg],0.68,112894,DB00802,Alfentanil
,8280548,plasma concentration,Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml-1) than in the control group (199 ng ml-1) (P < 0.02).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ng] / [ml],359,112895,DB00802,Alfentanil
,8280548,plasma concentration,Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml-1) than in the control group (199 ng ml-1) (P < 0.02).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ng] / [ml],199,112896,DB00802,Alfentanil
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,45,113314,DB00802,Alfentanil
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,4.4,113315,DB00802,Alfentanil
,16291719,E(max),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),mm,2.5,116660,DB00802,Alfentanil
,16291719,gamma,"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),,2.5,116661,DB00802,Alfentanil
,16291719,EC(50),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),[ng] / [ml],76.8,116662,DB00802,Alfentanil
,16291719,E(max),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),mm,2.8,116663,DB00802,Alfentanil
,16291719,EC(50),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),[ng] / [ml],19.9,116664,DB00802,Alfentanil
,3126050,maintenance infusion rate,The maintenance infusion rate of approximately 1 microgram kg-1 min-1 results in steady-state plasma levels in the therapeutic range in most patients.,The pharmacokinetic basis of alfentanil infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126050/),[μg] / [kg·min],1,119070,DB00802,Alfentanil
,2905588,isoflurane,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120712,DB00802,Alfentanil
,2905588,concentration,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120713,DB00802,Alfentanil
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB00802,Alfentanil
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB00802,Alfentanil
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB00802,Alfentanil
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB00802,Alfentanil
,2875679,steady state plasma concentration (Css),"In a group of seven patients undergoing intracranial surgery under neurolept anesthesia, an alfentanil infusion was initiated with a loading dose of 235 micrograms/kg over 5 min, followed by a maintenance infusion rate of 1.8 microgram X kg-1 X min-1 in order to obtain a steady state plasma concentration (Css) of 400 ng/ml-1 according to an infusion model.",The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875679/),[ng] / [ml],400,124664,DB00802,Alfentanil
,2875679,Css,The mean values of Css (446 +/- 209 ng/ml) were close to the predicted ones.,The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875679/),[ng] / [ml],446,124665,DB00802,Alfentanil
,2875679,hepatic extraction coefficient,Alfentanil plasma clearance did not differ from alfentanil hepatic clearance and alfentanil hepatic extraction coefficient values ranged from 0.32-0.53.,The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875679/),,0.32-0.53,124666,DB00802,Alfentanil
,2053728,first distribution half-life,"In dogs, compared with rabbits and sheep, the first distribution half-life was longer, probably because of pronounced drug-induced bradycardia (mean +/- SD, 48 +/- 21 beats/min).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[beats] / [min],48,125031,DB00802,Alfentanil
,2053728,Elimination half-life,"Elimination half-life was similar in all species (rabbits, 62.4 +/- 11.3 minutes; sheep, 65.1 +/- 27.1 minutes; dogs, 58.3 +/- 10.3 minutes).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),min,62.4,125032,DB00802,Alfentanil
,2053728,Elimination half-life,"Elimination half-life was similar in all species (rabbits, 62.4 +/- 11.3 minutes; sheep, 65.1 +/- 27.1 minutes; dogs, 58.3 +/- 10.3 minutes).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),min,65.1,125033,DB00802,Alfentanil
,2053728,Elimination half-life,"Elimination half-life was similar in all species (rabbits, 62.4 +/- 11.3 minutes; sheep, 65.1 +/- 27.1 minutes; dogs, 58.3 +/- 10.3 minutes).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),min,58.3,125034,DB00802,Alfentanil
,2053728,steady-state volume of distribution,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg],908.3,125035,DB00802,Alfentanil
,2053728,steady-state volume of distribution,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg],720.0,125036,DB00802,Alfentanil
,2053728,steady-state volume of distribution,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg],597.7,125037,DB00802,Alfentanil
,2053728,systemic clearance,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg·min],19.4,125038,DB00802,Alfentanil
,2053728,systemic clearance,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg·min],13.3,125039,DB00802,Alfentanil
,2053728,systemic clearance,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg·min],18.7,125040,DB00802,Alfentanil
,14616320,k(elCO2) (elimination rate constant of CO2,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),1/[min],0.144,127216,DB00802,Alfentanil
,14616320,F,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),,4.0,127217,DB00802,Alfentanil
,14616320,C50,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),[μg] / [l],61.3,127218,DB00802,Alfentanil
,14616320,k,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),1/[min],0.654,127219,DB00802,Alfentanil
,14616320,k,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),1/[min],0.023,127220,DB00802,Alfentanil
greater,21382685,recoveries,"Alfentanil and midazolam were extracted from plasma using a mixed-mode cation exchange solid phase extraction method, with recoveries of both compounds greater than 80% at 3 different concentrations (1, 10 and 100ng/ml).",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),%,80,128197,DB00802,Alfentanil
,21382685,flow rate,"Compounds were analyzed on a C(18) column with a water and methanol mobile phase gradient with acetic acid as an additive, at a flow rate of 0.3ml/min.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),[ml] / [min],0.3,128198,DB00802,Alfentanil
,21382685,signal to noise ratio,"The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),,80,128199,DB00802,Alfentanil
,21382685,signal to noise ratio,"The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),,40,128200,DB00802,Alfentanil
,10638903,rate constant,"Decreasing core temperature over 38.0-34.0 degrees C decreases the plasma clearance of vecuronium (11.3% per degrees C), decreases the rate constant for drug equilibration between plasma and effect site (0.023 min(-1) per degrees C), and increases the slope of the concentration-response relationship (0.43 per degrees C).",Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638903/),1/[c·degrees·min],0.023,128475,DB00802,Alfentanil
,8363073,MEACs,The MEACs ranged from < 1 to 175 ng/ml and showed substantial interindividual variability.,Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],1 to 175,133512,DB00802,Alfentanil
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],59,133513,DB00802,Alfentanil
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],52,133514,DB00802,Alfentanil
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],65,133515,DB00802,Alfentanil
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],43,133516,DB00802,Alfentanil
,2505988,apparent volume of distribution,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[l] / [kg],1.0,134355,DB00802,Alfentanil
,2505988,apparent volume of distribution,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[l] / [kg],0.48,134356,DB00802,Alfentanil
,2505988,clearance,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[ml] / [kg·min],2.2,134357,DB00802,Alfentanil
,2505988,clearance,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[ml] / [kg·min],5.6,134358,DB00802,Alfentanil
,2505988,elimination half-life,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),min,525,134359,DB00802,Alfentanil
,2505988,elimination half-life,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),min,60,134360,DB00802,Alfentanil
,7925209,clearance,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[ml] / [kg·min],5.2,136530,DB00802,Alfentanil
,7925209,terminal half-life,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),min,69,136531,DB00802,Alfentanil
,7925209,distribution volume at steady state,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[l] / [kg],0.22,136532,DB00802,Alfentanil
,7925209,Cumulative urinary excretion,Cumulative urinary excretion was around 18% within 24 h.,Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),%,18,136533,DB00802,Alfentanil
,2897149,Vc,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],82,139625,DB00802,Alfentanil
,2897149,VDSS,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],277,139626,DB00802,Alfentanil
,2897149,clearance,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg·min],2.01,139627,DB00802,Alfentanil
,2897149,t1/2 beta,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),min,117,139628,DB00802,Alfentanil
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,5944,139629,DB00802,Alfentanil
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,1240,139630,DB00802,Alfentanil
,11493236,time to patient comfort,The mean (SD) time to patient comfort was 27.6 (20.2) min for the mixture and 41.2 (18.6) min for morphine (p = 0.01).,A mixture of alfentanil and morphine for rapid postoperative loading with opioid: theoretical basis and initial clinical investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493236/),min,27.6,140705,DB00802,Alfentanil
,11493236,time to patient comfort,The mean (SD) time to patient comfort was 27.6 (20.2) min for the mixture and 41.2 (18.6) min for morphine (p = 0.01).,A mixture of alfentanil and morphine for rapid postoperative loading with opioid: theoretical basis and initial clinical investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493236/),min,41.2,140706,DB00802,Alfentanil
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],114.8,140727,DB00802,Alfentanil
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],158.8,140728,DB00802,Alfentanil
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],187.4,140729,DB00802,Alfentanil
,1642933,Mean residence time,Mean residence time was prolonged in the alcoholic group compared with controls (284.9 (217.8-362.2) min vs 226.8 (201.2-250) min).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),min,284.9,140730,DB00802,Alfentanil
,1642933,Mean residence time,Mean residence time was prolonged in the alcoholic group compared with controls (284.9 (217.8-362.2) min vs 226.8 (201.2-250) min).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),min,226.8,140731,DB00802,Alfentanil
,19238656,hepatic,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141867,DB00802,Alfentanil
,19238656,intestinal extraction,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141868,DB00802,Alfentanil
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,37,141869,DB00802,Alfentanil
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,95,141870,DB00802,Alfentanil
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],4.6,142800,DB00802,Alfentanil
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],4.8,142801,DB00802,Alfentanil
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],3.9,142802,DB00802,Alfentanil
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],7.8,142803,DB00802,Alfentanil
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],7.7,142804,DB00802,Alfentanil
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],6.0,142805,DB00802,Alfentanil
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],11.8,142806,DB00802,Alfentanil
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],13.3,142807,DB00802,Alfentanil
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],12.6,142808,DB00802,Alfentanil
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],35.2,142809,DB00802,Alfentanil
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],36.4,142810,DB00802,Alfentanil
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],29.4,142811,DB00802,Alfentanil
,9197301,half-lives of equilibrium,"The half-lives of equilibrium between blood and brain were 6.3 and 0.8 min for meperidine and alfentanil, respectively: The rate of penetration of both opioids into the brain was rapid and not rate-limiting.",The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197301/),min,6.3,145020,DB00802,Alfentanil
,9197301,half-lives of equilibrium,"The half-lives of equilibrium between blood and brain were 6.3 and 0.8 min for meperidine and alfentanil, respectively: The rate of penetration of both opioids into the brain was rapid and not rate-limiting.",The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197301/),min,0.8,145021,DB00802,Alfentanil
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],56,147482,DB00802,Alfentanil
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],28,147483,DB00802,Alfentanil
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],14,147484,DB00802,Alfentanil
,3120765,free fractions,"The degree of plasma protein binding was also similar in children and adults with mean free fractions of 11.5 +/- 0.9% (+/- SD) and 11.8 +/- 3.9%, respectively.",Pharmacokinetics of alfentanil in children undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),%,11.5,148142,DB00802,Alfentanil
,3120765,free fractions,"The degree of plasma protein binding was also similar in children and adults with mean free fractions of 11.5 +/- 0.9% (+/- SD) and 11.8 +/- 3.9%, respectively.",Pharmacokinetics of alfentanil in children undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),%,11.8,148143,DB00802,Alfentanil
,3120765,elimination half-life,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),min,63,148144,DB00802,Alfentanil
,3120765,elimination half-life,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),min,95,148145,DB00802,Alfentanil
,3120765,plasma clearance,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),[ml] / [kg·min],11.1,148146,DB00802,Alfentanil
,3120765,plasma clearance,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),[ml] / [kg·min],5.9,148147,DB00802,Alfentanil
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,3.9,149435,DB00802,Alfentanil
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,1.2,149436,DB00802,Alfentanil
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,107,149437,DB00802,Alfentanil
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,31,149438,DB00802,Alfentanil
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],20,149439,DB00802,Alfentanil
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],18,149440,DB00802,Alfentanil
,6416281,distribution half-life,"The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),min,7.4,149511,DB00802,Alfentanil
,6416281,elimination half-life,"The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),min,86.7,149512,DB00802,Alfentanil
,6416281,"apparent volume of distribution, Varea","The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),[l] / [kg],0.44,149513,DB00802,Alfentanil
,6416281,elimination clearance,"The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),[ml] / [kg·min],3.33,149514,DB00802,Alfentanil
,6416281,steady state plasma concentration,"These values for apparent volume of distribution and clearance can be used to calculate correct bolus and infusion doses to maintain any desired steady state plasma concentration using standard formulae: for example, to maintain a steady state plasma concentration of 400 ng ml-1, a bolus dose of 176 micrograms kg-1 and an infusion of 1.3 micrograms kg-1 min1 would be required.",Pharmacokinetics of the infusion of alfentanil in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),[ng] / [ml],400,149515,DB00802,Alfentanil
,1610997,steady-state volume of distribution (Vss,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg],258,150037,DB00802,Alfentanil
,1610997,elimination clearance (Cle,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],10.7,150038,DB00802,Alfentanil
,1610997,distribution clearance (Cld,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],6.8,150039,DB00802,Alfentanil
,1610997,Vss,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg],"1,107",150040,DB00802,Alfentanil
,1610997,Cle,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],20.0,150041,DB00802,Alfentanil
,1610997,Cld,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],23.0,150042,DB00802,Alfentanil
,1610997,distribution half-life (t1/2 lambda 1,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,2.8,150043,DB00802,Alfentanil
,1610997,elimination half-life (t1/2 lambda 2,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,36,150044,DB00802,Alfentanil
,1610997,t1/2 lambda 1,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,1.7,150045,DB00802,Alfentanil
,1610997,t1/2 lambda 2,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,68,150046,DB00802,Alfentanil
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.62,159632,DB00802,Alfentanil
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.81,159633,DB00802,Alfentanil
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.60,159634,DB00802,Alfentanil
,9723968,clearance,"The values (mean+/-s.e., n=20) of clearance, volume of distribution at steady-state and terminal half-life were 45+/-3 ml x min(-1) x kg(-1), 0.91+/-0.09 l/kg(-1) and 23+/-1 min, respectively, and independent of the administered dose.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[ml] / [kg·min],45,160328,DB00802,Alfentanil
,9723968,volume of distribution at steady-state,"The values (mean+/-s.e., n=20) of clearance, volume of distribution at steady-state and terminal half-life were 45+/-3 ml x min(-1) x kg(-1), 0.91+/-0.09 l/kg(-1) and 23+/-1 min, respectively, and independent of the administered dose.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[l] / [kg],0.91,160329,DB00802,Alfentanil
,9723968,terminal half-life,"The values (mean+/-s.e., n=20) of clearance, volume of distribution at steady-state and terminal half-life were 45+/-3 ml x min(-1) x kg(-1), 0.91+/-0.09 l/kg(-1) and 23+/-1 min, respectively, and independent of the administered dose.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),min,23,160330,DB00802,Alfentanil
,9723968,E0,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),μv,56,160331,DB00802,Alfentanil
,9723968,Emax,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),μv,93,160332,DB00802,Alfentanil
,9723968,EC50,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[ng] / [ml],235,160333,DB00802,Alfentanil
,9723968,Hill factor,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),,1.6,160334,DB00802,Alfentanil
,9723968,EC50,"For the second of the two consecutive infusions a significantly higher value of the EC50 of 404+/-56 ng x ml(-1) was observed (P < 0.05), while the values of the other pharmacodynamic parameters were unchanged.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[ng] / [ml],404,160335,DB00802,Alfentanil
,1989741,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state (Vdss) were 0.44 +/- 0.022 and 0.63 +/- 0.32 L.kg-1, respectively.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[l] / [kg],0.44,163236,DB00802,Alfentanil
,1989741,volume of distribution at steady state (Vdss),"The volume of the central compartment and the volume of distribution at steady state (Vdss) were 0.44 +/- 0.022 and 0.63 +/- 0.32 L.kg-1, respectively.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[l] / [kg],0.63,163237,DB00802,Alfentanil
,1989741,Total drug clearance,Total drug clearance was 6.4 = 1.9 ml.min-1.kg-1.,Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[ml] / [kg·min],6.4,163238,DB00802,Alfentanil
,1989741,elimination half-time,The elimination half-time was 3.7 +/- 2.6 hr.,Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),h,3.7,163239,DB00802,Alfentanil
,1989741,elimination half-time,"In general surgical patients, the elimination half-time of alfentanil has been reported to be 1.2-2.0 hr.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),h,1.2-2.0,163240,DB00802,Alfentanil
,8130056,PaCO2,Halothane was maintained at 1.05-1.07% end-tidal concentration with a PaCO2 of 6-7.3 kPa.,Effect of xylazine and ketamine on the pharmacokinetics of alfentanil during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130056/),kpa,6-7.3,164456,DB00802,Alfentanil
,2573716,binding to,"Alfentanil binding to plasma proteins was 87.6% (s.d. 2.0) in the patients with chronic renal failure, and 89.7% (1.2) in patients with normal renal function (P = 0.025).",Disposition of alfentanil in patients receiving a renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),%,87.6,165750,DB00802,Alfentanil
,2573716,binding to,"Alfentanil binding to plasma proteins was 87.6% (s.d. 2.0) in the patients with chronic renal failure, and 89.7% (1.2) in patients with normal renal function (P = 0.025).",Disposition of alfentanil in patients receiving a renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),%,89.7,165751,DB00802,Alfentanil
,2573716,Elimination half life,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,142.4,165752,DB00802,Alfentanil
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,120.2,165753,DB00802,Alfentanil
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,128.5,165754,DB00802,Alfentanil
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,136.0,165755,DB00802,Alfentanil
,2573716,apparent volume of distribution at steady state,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,40.5,165756,DB00802,Alfentanil
,2573716,apparent volume of distribution at steady state,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,27.6,165757,DB00802,Alfentanil
,2573716,Total drug clearance,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),[ml] / [min],341.9,165758,DB00802,Alfentanil
,2573716,Total drug clearance,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),[ml] / [min],211.8,165759,DB00802,Alfentanil
,2573716,Vd area,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,69.3,165760,DB00802,Alfentanil
,2573716,Vd area,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,35.5,165761,DB00802,Alfentanil
more,8214669,clearance,Five sets from the literature also showed a reliable predictive accuracy but four other sets with a clearance more than 5 mL.kg-1.min-1 and derived from a large bolus injection were inaccurate (MDAPE > 50%) as they underestimated the alfentanil concentrations.,Predictive accuracy of continuous alfentanil infusion in volunteers: variability of different pharmacokinetic sets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214669/),[ml] / [kg·min],5,169393,DB00802,Alfentanil
,7586903,clearance,"Remifentanil undergoes widespread extrahepatic metabolism by blood and tissue nonspecific esterases, resulting in an extremely rapid clearance of approximately 3 L/min (180 L/h).",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),[l] / [min],3,173335,DB00802,Alfentanil
,7586903,steady-state volume of distribution,"Like the other members of this class of drugs, remifentanil is lipophilic and is widely distributed in body tissues with a steady-state volume of distribution of approximately 30L.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),l,30,173336,DB00802,Alfentanil
,7586903,half-time,"Determined by computer simulation, the context-sensitive half-time of remifentanil is approximately 3 minutes, and is independent of infusion duration.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,3,173337,DB00802,Alfentanil
,7586903,t1/2ke0,"Speed of onset of effect is very rapid and is similar to that of alfentanil, which is reflected in a t1/2ke0 (a parameter used to characterise the delay between peak blood drug concentration and peak pharmacodynamic effect utilising a theoretical effect compartment) of approximately 1 to 2 minutes.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,1 to 2,173338,DB00802,Alfentanil
,2339802,terminal half-life,"However, simulation beyond 24 h after a bolus administration showed a terminal half-life of 20 h for fentanyl, i.e., an elimination phase that has not yet been described in actual pharmacokinetic studies.",Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339802/),h,20,175155,DB00802,Alfentanil
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],0.64,176375,DB00802,Alfentanil
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),,9.35,176376,DB00802,Alfentanil
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],5.53,176377,DB00802,Alfentanil
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],15.3,176378,DB00802,Alfentanil
,28001306,plasma concentration (Cp),"In the randomized controlled trial, the authors explored the role of the increase in CO by doxapram (plasma concentration (Cp) 1,000-3,500 ng/mL) on the pharmacokinetics (PKs) and pharmacodynamics (PDs) of the potent opioid alfentanil (Cp 100-200 ng/mL).",Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28001306/),[ng] / [ml],"1,000-3,500",177435,DB00802,Alfentanil
,28001306,Cp,"In the randomized controlled trial, the authors explored the role of the increase in CO by doxapram (plasma concentration (Cp) 1,000-3,500 ng/mL) on the pharmacokinetics (PKs) and pharmacodynamics (PDs) of the potent opioid alfentanil (Cp 100-200 ng/mL).",Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28001306/),[ng] / [ml],100-200,177436,DB00802,Alfentanil
,7486182,half-time,The modelled context-sensitive half-time for a 3-h infusion of alfentanil is 50-55 min and is 3 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,50-55,177586,DB00802,Alfentanil
,7486182,half-time,The modelled context-sensitive half-time for a 3-h infusion of alfentanil is 50-55 min and is 3 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,3,177587,DB00802,Alfentanil
,7486182,terminal elimination half-life,The terminal elimination half-life is 111 min for alfentanil and 12-30 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,111,177588,DB00802,Alfentanil
,7486182,terminal elimination half-life,The terminal elimination half-life is 111 min for alfentanil and 12-30 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,12-30,177589,DB00802,Alfentanil
,7486182,half-time,"The measured pharmacokinetic context-sensitive half-time for remifentanil after a 3-h infusion was 3.2 +/- 0.9 min, and its pharmacodynamic offset was 5.4 +/- 1.8 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,3.2,177590,DB00802,Alfentanil
,7486182,half-time,"The measured pharmacokinetic context-sensitive half-time for remifentanil after a 3-h infusion was 3.2 +/- 0.9 min, and its pharmacodynamic offset was 5.4 +/- 1.8 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,5.4,177591,DB00802,Alfentanil
,7486182,context-sensitive half-time,"Alfentanil's measured pharmacokinetic context-sensitive half-time was 47.3 +/- 12 min, and its pharmacodynamic offset was 54.0 +/- 48 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,47.3,177592,DB00802,Alfentanil
,7486182,offset,"Alfentanil's measured pharmacokinetic context-sensitive half-time was 47.3 +/- 12 min, and its pharmacodynamic offset was 54.0 +/- 48 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,54.0,177593,DB00802,Alfentanil
,7486182,terminal elimination half-life,The terminal elimination half-life modelled from the volunteers was 11.8 +/- 5.1 min for remifentanil and 76.5 +/- 12.6 min for alfentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,11.8,177594,DB00802,Alfentanil
,7486182,terminal elimination half-life,The terminal elimination half-life modelled from the volunteers was 11.8 +/- 5.1 min for remifentanil and 76.5 +/- 12.6 min for alfentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,76.5,177595,DB00802,Alfentanil
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180275,DB00802,Alfentanil
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180276,DB00802,Alfentanil
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.52,180277,DB00802,Alfentanil
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180278,DB00802,Alfentanil
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180279,DB00802,Alfentanil
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.28,180280,DB00802,Alfentanil
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180281,DB00802,Alfentanil
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180282,DB00802,Alfentanil
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180283,DB00802,Alfentanil
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,34.7,180284,DB00802,Alfentanil
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,10.9,180285,DB00802,Alfentanil
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180286,DB00802,Alfentanil
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.99,180287,DB00802,Alfentanil
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180288,DB00802,Alfentanil
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.69,180289,DB00802,Alfentanil
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180290,DB00802,Alfentanil
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180291,DB00802,Alfentanil
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.16,180292,DB00802,Alfentanil
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,1.0,180293,DB00802,Alfentanil
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.85,180294,DB00802,Alfentanil
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,339,180295,DB00802,Alfentanil
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180296,DB00802,Alfentanil
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,6.7,180297,DB00802,Alfentanil
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],0.3 to 97.3,181080,DB00802,Alfentanil
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],6.7,181081,DB00802,Alfentanil
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],402.8,181082,DB00802,Alfentanil
,8541435,total dose,Over a period of 69.2 +/- 39.8 min during resection of the tumor the total dose was 7017 +/- 12433 micrograms.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),μg,7017,181083,DB00802,Alfentanil
,8311274,elimination half-time (t1/2 beta,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),min,180,182815,DB00802,Alfentanil
,8311274,central distribution volume (Vc,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.25,182816,DB00802,Alfentanil
,8311274,total volume of distribution (Vdss,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.63,182817,DB00802,Alfentanil
,8311274,Vd area,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.92,182818,DB00802,Alfentanil
,27435752,Racc,"Finally, the model was refined to incorporate the fractional contribution of enzymes, including CYP2B6, propagating autoinduction into the model (Racc 1.7 vs. 1.7 observed).",Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435752/),,1.7,183894,DB00802,Alfentanil
,9403781,clearance,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[min·ml] / [kg],53,184989,DB00802,Alfentanil
,9403781,volume of distribution,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[l] / [kg],1.19,184990,DB00802,Alfentanil
,9403781,terminal half-life,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),min,24.5,184991,DB00802,Alfentanil
,9403781,E0,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),μv,57,184992,DB00802,Alfentanil
,9403781,Emax,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),μv,95,184993,DB00802,Alfentanil
,9403781,EC50,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[ng] / [ml],202,184994,DB00802,Alfentanil
,9403781,Hill factor,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),,1.53,184995,DB00802,Alfentanil
,15087613,elimination clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.1,186485,DB00802,Alfentanil
,15087613,elimination clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],1.9,186486,DB00802,Alfentanil
,15087613,distribution clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.7,186487,DB00802,Alfentanil
,15087613,distribution clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.0,186488,DB00802,Alfentanil
,15087613,peripheral volume of distribution,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),l,179,186489,DB00802,Alfentanil
,15087613,peripheral volume of distribution,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),l,141,186490,DB00802,Alfentanil
,3148286,infusion rate,The infusion rate was reduced to 0.5 microgram/kg/min after ten minutes.,A comparison of alfentanil requirements in European and Asian patients during general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148286/),[μg] / [kg·min],0.5,189989,DB00802,Alfentanil
,34407992,CLint,Fetal hepatic clearance of fentanyl was predicted from CYP3A7 mediated norfentanyl formation in fetal liver microsomes (CLint = 0.20 {plus minus} 0.05 µL/min/mg protein).,Predicting maternal-fetal disposition of fentanyl following intravenous and epidural administration using physiologically-based pharmacokinetic modeling. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34407992/),[μl] / [mg·min],0.20,190221,DB00802,Alfentanil
,8105723,volume of distribution,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),[l] / [kg],0.39,190760,DB00802,Alfentanil
,8105723,volume of distribution,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),[l] / [kg],0.52,190761,DB00802,Alfentanil
,8105723,distribution phase,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,0.94,190762,DB00802,Alfentanil
,8105723,elimination half-life,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,9.5,190763,DB00802,Alfentanil
,8105723,elimination half-life,"Remifentanil had a small volume of distribution of 0.39 (SD, +/- 0.25) L/kg (alfentanil, 0.52 +/- 2 L/kg), with a rapid distribution phase of 0.94 (SD, +/- 0.57) min and an extremely short elimination half-life of 9.5 (SD, +/- 4) min compared with an elimination half-life of alfentanil of 58 (SD, +/- 7.6) min.",Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,58,190764,DB00802,Alfentanil
,8105723,t1/2 ke0 (half-time,The t1/2 ke0 (half-time for equilibration between plasma and the effect compartment) of remifentanil for analgesia was calculated as 1.3 min.,Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105723/),min,1.3,190765,DB00802,Alfentanil
,3134933,total plasma clearance,The total plasma clearance ranged between 93 and 431 ml min-1 (mean 249 ml min-1).,Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[ml] / [min],249,191911,DB00802,Alfentanil
,3134933,apparent volume of distribution at steady-state,The apparent volume of distribution at steady-state ranged between 0.27 and 0.64 litre kg-1 (mean 0.44 litre kg-1).,Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[l] / [kg],0.44,191912,DB00802,Alfentanil
,3134933,apparent volume of distribution (Vd beta),"The apparent volume of distribution (Vd beta) was 0.58 litre kg-1, resulting in a terminal half-life of 112 min.",Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[l] / [kg],0.58,191913,DB00802,Alfentanil
,3134933,terminal half-life,"The apparent volume of distribution (Vd beta) was 0.58 litre kg-1, resulting in a terminal half-life of 112 min.",Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),min,112,191914,DB00802,Alfentanil
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,4.6,192750,DB00802,Alfentanil
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,5.6,192751,DB00802,Alfentanil
,12131108,clearance,"Hypothermia did not change the clearance (696 ml/min), maximum effect, or duration of action of neostigmine.",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),[ml] / [min],696,192752,DB00802,Alfentanil
,1467073,protein binding,The mean protein binding of alfentanil was 94.2 (SEM 0.05)% in the burns group and 90.7 (0.4)% in the control group (P = 0.004).,Disposition of alfentanil in burns patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467073/),%,94.2,197958,DB00802,Alfentanil
,1467073,protein binding,The mean protein binding of alfentanil was 94.2 (SEM 0.05)% in the burns group and 90.7 (0.4)% in the control group (P = 0.004).,Disposition of alfentanil in burns patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467073/),%,90.7,197959,DB00802,Alfentanil
,15907650,half-lives,Alfentanil and remifentanil are very fast equilibrating opioids with equilibration half-lives between plasma and effect site of about 1 minute.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,1,199979,DB00802,Alfentanil
,15907650,half-lives,"They are followed by fentanyl and sufentanil, each with equilibration half-lives of about 6 min.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,6,199980,DB00802,Alfentanil
,15907650,half-life,Methadone equilibrates with a half-life of about 8 min.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,8,199981,DB00802,Alfentanil
,15907650,half-life,"Morphine, in contrast, equilibrates with a half-life of 2-3 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,2-3,199982,DB00802,Alfentanil
,15907650,half-life,"The slowest opioid with respect to plasma-effect site transfer is M6G, with an equilibration half-life of about 7 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,7,199983,DB00802,Alfentanil
,9661572,clearance,Alfentanil clearance was decreased from 3.1 +/- 1.1 mL.min-1.kg-1 to 1.3 +/- 0.3 mL.min-1.,The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661572/),[ml] / [kg·min],3.1,204213,DB00802,Alfentanil
,9661572,clearance,Alfentanil clearance was decreased from 3.1 +/- 1.1 mL.min-1.kg-1 to 1.3 +/- 0.3 mL.min-1.,The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661572/),[ml] / [min],1.3,204214,DB00802,Alfentanil
,2903758,T1/2fast,"During the following 14 min, fentanyl was released, apparently from two binding sites (T1/2fast: 0.22 (0.16-0.27) min; T1/2slow: 5.78 (3.65-13.86) min).",Pulmonary kinetics of fentanyl and alfentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903758/),min,0.22,204687,DB00802,Alfentanil
,2903758,T1/2slow,"During the following 14 min, fentanyl was released, apparently from two binding sites (T1/2fast: 0.22 (0.16-0.27) min; T1/2slow: 5.78 (3.65-13.86) min).",Pulmonary kinetics of fentanyl and alfentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903758/),min,5.78,204688,DB00802,Alfentanil
,2903758,T1/2,"Initially, there was a rapid release of alfentanil (T1/2: 0.28 (0.08-0.51) min).",Pulmonary kinetics of fentanyl and alfentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903758/),min,0.28,204689,DB00802,Alfentanil
,7978186,peak plasma concentrations,The peak plasma concentrations were P 10.6 +/- 1.5 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,10.6,207603,DB00802,Alfentanil
,7978186,M,ml-1 and M 12.4 +/- 2.6 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,12.4,207604,DB00802,Alfentanil
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,15,207605,DB00802,Alfentanil
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,50,207606,DB00802,Alfentanil
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,25,207607,DB00802,Alfentanil
,6122384,plasma half-life,"The plasma half-life of alfentanyl in the alpha-phase was about 4 min, the elimination half-life was 70 min.",[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),min,4,208264,DB00802,Alfentanil
,6122384,elimination half-life,"The plasma half-life of alfentanyl in the alpha-phase was about 4 min, the elimination half-life was 70 min.",[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),min,70,208265,DB00802,Alfentanil
,6122384,total volume of distribution,The total volume of distribution was calculated to 33 1.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),1,33,208266,DB00802,Alfentanil
,6122384,total plasma clearance,The total plasma clearance amounted to 336 ml/min.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),[ml] / [min],336,208267,DB00802,Alfentanil
,6122384,Plasma protein binding,Plasma protein binding of alfentanyl was about 92%; binding to human erythrocytes showed values less than 0.1%.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),%,92,208268,DB00802,Alfentanil
less,6122384,Plasma protein binding,Plasma protein binding of alfentanyl was about 92%; binding to human erythrocytes showed values less than 0.1%.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),%,0.1,208269,DB00802,Alfentanil
,6122384,renal excretion,The renal excretion of unchanged alfentanyl amounted to only 0.4% of the total dose in a time period of 24h.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),%,0.4,208270,DB00802,Alfentanil
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1,208483,DB00802,Alfentanil
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.4,208484,DB00802,Alfentanil
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.0,208485,DB00802,Alfentanil
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2,208486,DB00802,Alfentanil
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,0.9,208487,DB00802,Alfentanil
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.0,208488,DB00802,Alfentanil
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.2,208489,DB00802,Alfentanil
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.3,208490,DB00802,Alfentanil
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,3.6,208491,DB00802,Alfentanil
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,5.3,208492,DB00802,Alfentanil
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.8,208493,DB00802,Alfentanil
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.9,208494,DB00802,Alfentanil
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.9,208495,DB00802,Alfentanil
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.4,208496,DB00802,Alfentanil
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.5,208497,DB00802,Alfentanil
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,6.9,208498,DB00802,Alfentanil
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.8,208499,DB00802,Alfentanil
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.9,208500,DB00802,Alfentanil
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.9,208501,DB00802,Alfentanil
,8531080,peak alfentanil concentrations,"Alfentanil was administered by use of three different drug infusion strategies in order to develop a pharmacokinetic-pharmacodynamic model for acute tolerance: I) intravenous infusion of 0.5 mg/kg in 10 min, achieving peak alfentanil concentrations of 750 ng/ml; II) computer-controlled infusion to rapidly achieve and maintain a constant drug level of 750 ng/ml, followed by washout; III) computer-controlled infusion to step through multiple constant drug levels (up to 1500 ng/ml), followed by washout.",Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),[ng] / [ml],750,210233,DB00802,Alfentanil
,8531080,Clearance,Clearance values ranged from (S.E.) 49.7 (2.8) ml/min/kg at low alfentanil concentrations to a minimum value of 29.3 (0.8) ml/min/kg at high concentrations.,Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),[ml] / [kg·min],49.7,210234,DB00802,Alfentanil
,8531080,minimum value,Clearance values ranged from (S.E.) 49.7 (2.8) ml/min/kg at low alfentanil concentrations to a minimum value of 29.3 (0.8) ml/min/kg at high concentrations.,Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),[ml] / [kg·min],29.3,210235,DB00802,Alfentanil
,8531080,half-life,Maximum tolerance diminished alfentanil's effect by 46% and was achieved with a half-life of 7.0 min.,Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),min,7.0,210236,DB00802,Alfentanil
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00802,Alfentanil
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00802,Alfentanil
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00802,Alfentanil
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00802,Alfentanil
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00802,Alfentanil
,1610996,Total sampling time,"Total sampling time before CPB (45 to 75 minutes) was too short to allow full characterization of the pharmacokinetics of alfentanil, but allowed estimation of the initial volume of distribution.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),min,45 to 75,214806,DB00802,Alfentanil
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214807,DB00802,Alfentanil
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214808,DB00802,Alfentanil
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214809,DB00802,Alfentanil
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],80,214810,DB00802,Alfentanil
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214811,DB00802,Alfentanil
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],179,214812,DB00802,Alfentanil
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],17.9,214813,DB00802,Alfentanil
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],18.3,214814,DB00802,Alfentanil
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],11.1,214815,DB00802,Alfentanil
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],12.9,214816,DB00802,Alfentanil
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],2.3,215709,DB00802,Alfentanil
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.2,215710,DB00802,Alfentanil
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],1.5,215711,DB00802,Alfentanil
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.1,215712,DB00802,Alfentanil
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,406,215713,DB00802,Alfentanil
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,87,215714,DB00802,Alfentanil
exceeding,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],300,215715,DB00802,Alfentanil
,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],400,215716,DB00802,Alfentanil
,7997393,clearance,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),[ml] / [kg·min],6.94,215860,DB00802,Alfentanil
,7997393,clearance,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),[ml] / [kg·min],3.47,215861,DB00802,Alfentanil
,7997393,elimination half-life,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),min,50.6,215862,DB00802,Alfentanil
,7997393,elimination half-life,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),min,90.7,215863,DB00802,Alfentanil
,2979128,maximum inspired concentration,"After intubation, anesthesia was maintained with nitrous oxide-oxygen and halothane to a maximum inspired concentration of 0.6%.",Alfentanil in infants and children with congenital heart defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),%,0.6,216495,DB00802,Alfentanil
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],8.2,216496,DB00802,Alfentanil
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],6.3,216497,DB00802,Alfentanil
,1879253,volume of distribution,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),[l] / [kg],0.46,219671,DB00802,Alfentanil
,1879253,volume of distribution,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),[l] / [kg],0.61,219672,DB00802,Alfentanil
,1879253,mean residence time,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,68.8,219673,DB00802,Alfentanil
,1879253,mean residence time,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,62.3,219674,DB00802,Alfentanil
,1879253,elimination half-life,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,47.7,219675,DB00802,Alfentanil
,1879253,elimination half-life,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,43.2,219676,DB00802,Alfentanil
,17178769,"steady-state brain-to-serum concentration ratio (K(p,brain","However, the steady-state brain-to-serum concentration ratio (K(p,brain,ss)) was approximately 3-fold lower in mdr1a(+/+) mice compared with mdr1a(-/-) mice (0.19 +/- 0.01 versus 0.54 +/- 0.04, respectively).",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),,0.19,222342,DB00802,Alfentanil
,17178769,"steady-state brain-to-serum concentration ratio (K(p,brain","However, the steady-state brain-to-serum concentration ratio (K(p,brain,ss)) was approximately 3-fold lower in mdr1a(+/+) mice compared with mdr1a(-/-) mice (0.19 +/- 0.01 versus 0.54 +/- 0.04, respectively).",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),,0.54,222343,DB00802,Alfentanil
,17178769,EC(50),"However, there was no difference in the antinociception versus brain concentration relationship, or in the brain tissue EC(50) (11 +/- 1.8 versus 9.2 +/- 1.7 ng/g), between mdr1a(+/+) and mdr1a(-/-) mice.",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),[ng] / [g],11,222344,DB00802,Alfentanil
,17178769,EC(50),"However, there was no difference in the antinociception versus brain concentration relationship, or in the brain tissue EC(50) (11 +/- 1.8 versus 9.2 +/- 1.7 ng/g), between mdr1a(+/+) and mdr1a(-/-) mice.",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),[ng] / [g],9.2,222345,DB00802,Alfentanil
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],24.84,226435,DB00802,Alfentanil
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],14.52,226436,DB00802,Alfentanil
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],19.44,226437,DB00802,Alfentanil
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],16.2,226438,DB00802,Alfentanil
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],15.2,227567,DB00802,Alfentanil
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],33.7,227568,DB00802,Alfentanil
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],45.5,227569,DB00802,Alfentanil
,10714844,saliva concentrations,"At 1, 2, 3, and 4 h after rectal dosing the saliva concentrations (mean+/-SD) were 15.2+/-5.9 micromol/l, 33.7+/-12.5 micromol/l, 45.5+/-19.1 micromol/l, and 55.4+/-23.1 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],55.4,227570,DB00802,Alfentanil
,10714844,serum concentrations,"The serum concentrations at 2 and 4 h were 31.0+/-11.2 micromol/l and 54.8+/-23.8 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],31.0,227571,DB00802,Alfentanil
,10714844,serum concentrations,"The serum concentrations at 2 and 4 h were 31.0+/-11.2 micromol/l and 54.8+/-23.8 micromol/l, respectively.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],54.8,227572,DB00802,Alfentanil
,10714844,saliva concentrations,"Additional oral dosing resulted in saliva concentrations at 5, 8, and 9 h of 99.7+/-49.5 micromol/l, 106.9+/-31.7 micromol/l, and 139.3+/-55.4 micromol/l, respectively, with coincident serum concentrations of 100.1 +/- 50.2 micromol/l, 105.6+/-29.0 micromol/l, and 141.2+/-52.1 micromol/l.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],99.7,227573,DB00802,Alfentanil
,10714844,saliva concentrations,"Additional oral dosing resulted in saliva concentrations at 5, 8, and 9 h of 99.7+/-49.5 micromol/l, 106.9+/-31.7 micromol/l, and 139.3+/-55.4 micromol/l, respectively, with coincident serum concentrations of 100.1 +/- 50.2 micromol/l, 105.6+/-29.0 micromol/l, and 141.2+/-52.1 micromol/l.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],106.9,227574,DB00802,Alfentanil
,10714844,saliva concentrations,"Additional oral dosing resulted in saliva concentrations at 5, 8, and 9 h of 99.7+/-49.5 micromol/l, 106.9+/-31.7 micromol/l, and 139.3+/-55.4 micromol/l, respectively, with coincident serum concentrations of 100.1 +/- 50.2 micromol/l, 105.6+/-29.0 micromol/l, and 141.2+/-52.1 micromol/l.",High-dose rectal and oral acetaminophen in postoperative patients--serum and saliva concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10714844/),[μM] / [l],139.3,227575,DB00802,Alfentanil
,6128948,t 1/2 pi,"The combined mean (+/- SEM) half-lives for the 11 patients for the rapid and slow distribution phases were short (t 1/2 pi = 1.2 +/- 0.26 min, t 1/2 alpha = 11.6 +/- 1.63 min).",The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),min,1.2,229931,DB00802,Alfentanil
,6128948,t 1/2 alpha,"The combined mean (+/- SEM) half-lives for the 11 patients for the rapid and slow distribution phases were short (t 1/2 pi = 1.2 +/- 0.26 min, t 1/2 alpha = 11.6 +/- 1.63 min).",The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),min,11.6,229932,DB00802,Alfentanil
,6128948,"elimination half-life, t 1/2 beta","The elimination half-life, t 1/2 beta was 94 +/- 5.87 min which is considerably shorter than that of other opioids.",The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),min,94,229933,DB00802,Alfentanil
,6128948,total body clearance,The mean (+/- SEM) total body clearance was 6.4 +/- 1.39 ml . kg-1 . min-1 and the volume of distribution (Vd) was 0.86 +/- 0.194 l/kg.,The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),[ml] / [kg·min],6.4,229934,DB00802,Alfentanil
,6128948,volume of distribution (Vd),The mean (+/- SEM) total body clearance was 6.4 +/- 1.39 ml . kg-1 . min-1 and the volume of distribution (Vd) was 0.86 +/- 0.194 l/kg.,The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),[l] / [kg],0.86,229935,DB00802,Alfentanil
,6124179,t 1/2 pi,"The disappearance of the drug from plasma was rapid (t 1/2 pi = 3.5 +/- 1.3 minutes, t 1/2 alpha = 16.8 +/- 6.4 minutes) with 96.4% of the drug eliminated from plasma in 1 hour, indicating extensive transfer to the remote peripheral compartment.",Pharmacokinetics of alfentanil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),min,3.5,230095,DB00802,Alfentanil
,6124179,t 1/2 alpha,"The disappearance of the drug from plasma was rapid (t 1/2 pi = 3.5 +/- 1.3 minutes, t 1/2 alpha = 16.8 +/- 6.4 minutes) with 96.4% of the drug eliminated from plasma in 1 hour, indicating extensive transfer to the remote peripheral compartment.",Pharmacokinetics of alfentanil in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),min,16.8,230096,DB00802,Alfentanil
,6124179,t 1/2 beta,This was followed by a slower elimination phase with a t 1/2 beta of 94 +/- 38 minutes.,Pharmacokinetics of alfentanil in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),min,94,230097,DB00802,Alfentanil
,6124179,Total volume of distribution,Total volume of distribution was 1.03 +/- 0.50 L/kg.,Pharmacokinetics of alfentanil in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),[l] / [kg],1.03,230098,DB00802,Alfentanil
,6124179,Total plasma clearance,Total plasma clearance was 456 +/- 155 ml/min.,Pharmacokinetics of alfentanil in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),[ml] / [min],456,230099,DB00802,Alfentanil
,6135368,plasma concentrations,Alfentanil plasma concentrations of 0.45 microgram/ml were maintained by the same infusion scheme beginning with skin incision until 20 minutes prior to the end of surgery.,Pharmacokinetics as applied to total intravenous anaesthesia. Practical implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135368/),[μg] / [ml],0.45,230377,DB00802,Alfentanil
,11573657,V1,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),l,4.88,231202,DB00802,Alfentanil
,11573657,V2,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),l,24.50,231203,DB00802,Alfentanil
,11573657,Cl2,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),[l] / [min],2.84,231204,DB00802,Alfentanil
,11573657,Cl3,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),[l] / [min],0.788,231205,DB00802,Alfentanil
,17112806,plasma clearance,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),[ml] / [kg·min],4.4,232835,DB00802,Alfentanil
,17112806,plasma clearance,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),[ml] / [kg·min],0.67,232836,DB00802,Alfentanil
,17112806,elimination half-life,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),h,1.5,232837,DB00802,Alfentanil
,17112806,elimination half-life,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),h,6.6,232838,DB00802,Alfentanil
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,60,233049,DB00802,Alfentanil
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,300,233050,DB00802,Alfentanil
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,1.5 to 6,233051,DB00802,Alfentanil
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,15,233052,DB00802,Alfentanil
,6226471,total body clearance,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),[l] / [min],0.4 to over 1.5,233053,DB00802,Alfentanil
,8969394,infusion rate,Patients were anesthetized using a continuous infusion of alfentanil (mean infusion rate: 1 microgram/kg/min) and propofol administered by TCI.,Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8969394/),[μg] / [kg·min],1,237365,DB00802,Alfentanil
,8969394,target concentrations,"In the period during and after bypass, the mean target concentrations required to maintain anesthesia was 2.22 micrograms/mL.",Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8969394/),[μg] / [ml],2.22,237366,DB00802,Alfentanil
,7914736,blood clearance,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[ml] / [kg·min],29.8,240059,DB00802,Alfentanil
,7914736,volume of distribution,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[l] / [kg],3.60,240060,DB00802,Alfentanil
,7914736,blood elimination half-life,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),min,144,240061,DB00802,Alfentanil
,22732112,initial effect-site target concentration,The initial effect-site target concentration was 100 ng ml(-1).,Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732112/),[ng] / [ml],100,241120,DB00802,Alfentanil
,3920934,plasma clearance,Patients with cirrhosis had a significantly lower (P less than 0.01) plasma clearance of alfentanil of 1.6 +/- 1.0 ml . min-1 . kg-1 (mean +/- SD) instead of 3.1 +/- 1.6 ml . min-1 . kg-1 in the controls.,Alfentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),[ml] / [kg·min],1.6,241168,DB00802,Alfentanil
,3920934,plasma clearance,Patients with cirrhosis had a significantly lower (P less than 0.01) plasma clearance of alfentanil of 1.6 +/- 1.0 ml . min-1 . kg-1 (mean +/- SD) instead of 3.1 +/- 1.6 ml . min-1 . kg-1 in the controls.,Alfentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),[ml] / [kg·min],3.1,241169,DB00802,Alfentanil
,3920934,elimination half-life,The elimination half-life was prolonged from 90 +/- 18 min in the controls to 219 +/- 128 min in the cirrhotics (P less than 0.01).,Alfentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),min,90,241170,DB00802,Alfentanil
,3920934,elimination half-life,The elimination half-life was prolonged from 90 +/- 18 min in the controls to 219 +/- 128 min in the cirrhotics (P less than 0.01).,Alfentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),min,219,241171,DB00802,Alfentanil
,3920934,plasma-free fraction,Patients with cirrhosis had a higher (P less than 0.01) alfentanil plasma-free fraction (18.6 +/- 9.4%) compared with the control patients (11.5 +/- 3.9%).,Alfentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),%,18.6,241172,DB00802,Alfentanil
,3920934,plasma-free fraction,Patients with cirrhosis had a higher (P less than 0.01) alfentanil plasma-free fraction (18.6 +/- 9.4%) compared with the control patients (11.5 +/- 3.9%).,Alfentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),%,11.5,241173,DB00802,Alfentanil
,7924121,Elimination clearance,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[l] / [min],0.444,244907,DB00802,Alfentanil
,7924121,Elimination clearance,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[l] / [min],0.184,244908,DB00802,Alfentanil
,7924121,steady-state distribution volume,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),l,37,244909,DB00802,Alfentanil
,7924121,steady-state distribution volume,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),l,23,244910,DB00802,Alfentanil
,7924121,elimination half-life,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,127,244911,DB00802,Alfentanil
,7924121,elimination half-life,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,114,244912,DB00802,Alfentanil
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,1.2,244913,DB00802,Alfentanil
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,0.6,244914,DB00802,Alfentanil
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],429,244915,DB00802,Alfentanil
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],577,244916,DB00802,Alfentanil
,7924121,maximal,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],429,244917,DB00802,Alfentanil
,7924121,maximal,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],577,244918,DB00802,Alfentanil
,9141924,hepatic extraction coefficient,The hepatic extraction coefficient was 0.14 for alfentanil and 0.35 for sufentanil.,Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9141924/),,0.14,249908,DB00802,Alfentanil
,9141924,hepatic extraction coefficient,The hepatic extraction coefficient was 0.14 for alfentanil and 0.35 for sufentanil.,Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9141924/),,0.35,249909,DB00802,Alfentanil
,7946365,target concentrations,Patients were anesthetized using a variable-rate infusion of alfentanil combined with midazolam in an attempt to achieve and maintain target concentrations of 100 ng/ml or 500 ng/ml.,Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ng] / [ml],100,258250,DB00802,Alfentanil
,7946365,target concentrations,Patients were anesthetized using a variable-rate infusion of alfentanil combined with midazolam in an attempt to achieve and maintain target concentrations of 100 ng/ml or 500 ng/ml.,Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ng] / [ml],500,258251,DB00802,Alfentanil
lower,7946365,clearance,"Two of the selected data sets of midazolam, with a clearance lower than 5 ml/kg/min, were very accurate (MDAPE less than 20%) in predicting low or high prebypass concentrations of midazolam in adult patients with good left ventricular function.",Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ml] / [kg·min],5,258252,DB00802,Alfentanil
,3099604,CL,"The mean CL and Vc for alfentanil in a 70-kg male, aged less than 40 yr, were estimated as 0.356 l/min and 7.77 l, respectively.",Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099604/),[l] / [min],0.356,258637,DB00802,Alfentanil
,3099604,Vc,"The mean CL and Vc for alfentanil in a 70-kg male, aged less than 40 yr, were estimated as 0.356 l/min and 7.77 l, respectively.",Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099604/),l,7.77,258638,DB00802,Alfentanil
,2363549,Vdc,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[l] / [kg],0.66,258834,DB00802,Alfentanil
,2363549,Vdc,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[l] / [kg],0.27,258835,DB00802,Alfentanil
,2363549,t1/2 pi,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,5.4,258836,DB00802,Alfentanil
,2363549,t1/2 pi,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,2.7,258837,DB00802,Alfentanil
,2363549,plasma clearance,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[ml] / [kg·min],17.2,258838,DB00802,Alfentanil
,2363549,plasma clearance,"Differences between groups (mean +/- SD values) included Vdc (P: 0.66 +/- 0.31 l.kg-1; A: 0.27 +/- 0.15 l.kg-1; p less than 0.01), t1/2 pi (P: 5.4 +/- 2.9 min; A: 2.7 +/- 5.7 min; p less than 0.05) and plasma clearance (P: 17.2 +/- 4.6 ml.kg-1.min-1; A: 10.9 +/- 3.3 ml.kg-1.min-1; p less than 0.05).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),[ml] / [kg·min],10.9,258839,DB00802,Alfentanil
,2363549,t1/2 alpha,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,37.1,258840,DB00802,Alfentanil
,2363549,t1/2 alpha,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,26.8,258841,DB00802,Alfentanil
,2363549,t1/2 beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,260,258842,DB00802,Alfentanil
,2363549,t1/2 beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,175,258843,DB00802,Alfentanil
,2363549,Vdss,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],2.5,258844,DB00802,Alfentanil
,2363549,Vdss,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],2.8,258845,DB00802,Alfentanil
,2363549,Vd beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],4.1,258846,DB00802,Alfentanil
,2363549,Vd beta,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),1/[kg],4.0,258847,DB00802,Alfentanil
,2363549,MRT,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,228,258848,DB00802,Alfentanil
,2363549,MRT,"No statistical difference was found between A and P groups for the following parameters: t1/2 alpha (37.1 +/- 12.0 min vs 26.8 + 15.1 min), t1/2 beta (260 +/- 99 min vs 175 +/- 99 min), Vdss (2.5 +/- 1.11.kg-1 vs 2.8 +/- 1.61.kg-1), Vd beta (4.1 +/- 2.41.kg-1 vs 4.0 +/- 2.21.kg-1), and MRT (228 +/- 80 min vs 172 +/- 101 min).",[Comparison of the pharmacokinetics of etomidate in children and in adults]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363549/),min,172,258849,DB00802,Alfentanil
,7598917,Maximal plasma concentrations,Maximal plasma concentrations were 20.1 ng/ml +/- 7.3 ng/ml after 9 minutes in the intranasal group.,Pharmacokinetics of intranasal alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),[ng] / [ml],20.1,263517,DB00802,Alfentanil
,7598917,concentrations,"At this measurement point, the intranasal alfentanil concentrations were 64.7% (18.7 ng/ml +/- 6.8 ng/ml) of the IV concentrations (28.9 ng/ml +/- 7.9 ng/ml).",Pharmacokinetics of intranasal alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),[ng] / [ml],18.7,263518,DB00802,Alfentanil
,7598917,concentrations,"At this measurement point, the intranasal alfentanil concentrations were 64.7% (18.7 ng/ml +/- 6.8 ng/ml) of the IV concentrations (28.9 ng/ml +/- 7.9 ng/ml).",Pharmacokinetics of intranasal alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),[ng] / [ml],28.9,263519,DB00802,Alfentanil
,7598917,bioavailability,The calculated bioavailability after intranasal administration was 64.96% +/- 26.3%.,Pharmacokinetics of intranasal alfentanil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),%,64.96,263520,DB00802,Alfentanil
,3129956,constant target plasma alfentanil concentration,Alfentanil was administered as an exponentially decreasing infusion using a computer-assisted infusion device with a constant target plasma alfentanil concentration of 300 ng/ml.,Disposition kinetics of propofol during alfentanil anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129956/),[ng] / [ml],300,265999,DB00802,Alfentanil
,3129956,elimination half-life,The elimination half-life of alfentanil was approximately 75 minutes (SD 21).,Disposition kinetics of propofol during alfentanil anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129956/),min,75,266000,DB00802,Alfentanil
,7902033,Total clearance,Total clearance (250-300 l/h) of remifentanil was independent of dose and was approximately three to four times greater than the normal hepatic blood flow.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),[l] / [h],250-300,266515,DB00802,Alfentanil
,7902033,Volume of distribution at steady state,Volume of distribution at steady state (25-40 l) also was independent of dose.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),l,25-40,266516,DB00802,Alfentanil
,7902033,terminal half-life,The terminal half-life of remifentanil ranged from 10 to 21 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,10 to 21,266517,DB00802,Alfentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,3.65,266518,DB00802,Alfentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,33.9,266519,DB00802,Alfentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,58.5,266520,DB00802,Alfentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,262,266521,DB00802,Alfentanil
,7902033,terminal half-life,The mean terminal half-life of GI90291 ranged from 88 to 137 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,88 to 137,266522,DB00802,Alfentanil
,3512140,elimination half-life,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,149,268206,DB00802,Alfentanil
,3512140,clearance,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.3,268207,DB00802,Alfentanil
,3512140,elimination half-life,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,83 to 137,268208,DB00802,Alfentanil
,3512140,clearance,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],4.37 to 6.47,268209,DB00802,Alfentanil
,3512140,distribution,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,28,268210,DB00802,Alfentanil
,3512140,terminal elimination half-lives,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,273 to 330,268211,DB00802,Alfentanil
,3512140,clearance,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.6 to 25,268212,DB00802,Alfentanil
,3512140,half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,2.1,268213,DB00802,Alfentanil
,3512140,elimination half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,47,268214,DB00802,Alfentanil
,2502166,Cl,"There was no significant decrease in Cl with age, although the lower values for Cl (100-200 ml min-1) were generally found in subjects older than 60 yr.",Pharmacokinetics of alfentanil during and after a fixed rate infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2502166/),[ml] / [min],100-200,271175,DB00802,Alfentanil
,8330593,distribution half-life,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),min,6,271699,DB00802,Alfentanil
,8330593,elimination half-life,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),min,87,271700,DB00802,Alfentanil
,8330593,initial volume of distribution,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),l,10,271701,DB00802,Alfentanil
,8330593,steady state volume of distribution,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),l,31,271702,DB00802,Alfentanil
,8330593,total body clearance,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),[ml] / [min],308,271703,DB00802,Alfentanil
,8330593,distribution clearance,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),[ml] / [min],656,271704,DB00802,Alfentanil
